Showing 3151-3160 of 4107 results for "".
- FDA Approves Dupixent for Moderate to Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-approves-dupixent-for-moderate-to-severe-atopic-dermatitis-in-adolescents/2459975/The FDA has approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 through 17 whose disease is not adequately controlled with topical prescription
- Calling All Students: Ortho Dermatologics Now Accepting Applications for the 2019 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/calling-all-students-ortho-dermatologics-now-accepting-applications-for-the-2019-aspire-higher-scholarship-program/2459978/Ortho Dermatologics is accepting applications for its 2019 Aspire Higher scholarship program, which will award $90,000 total in scholarships to nine students who have been treated for a dermatologic condition. Students can apply for the Aspire Higher scholarship through April 26, 2
- Patricia Altavilla Named New CEO at Suneva Medicalhttps://practicaldermatology.com/news/patricia-altavilla-named-new-ceo-at-suneva-medical/2459982/Patricia Altavilla is the new Chief Executive Officer of Suneva® Medical, Inc. An industry vet, Altavilla began her career at Mentor Corporation, serving as Vice President of International Sales and Worldwide Marketing. For n
- Almirall: Positive Data for KX2-391 for AKs; ThermiGen to be Divestedhttps://practicaldermatology.com/news/almirall-positive-data-for-kx2-391-for-aks-thermigen-to-be-divested/2459986/Results from two Phase III studies of KX2-391, also known as KX-01 ointment, in the treatment of actinic keratosis show positive results. The findings have been presented at the 2019 American Academy of Dermatology Annual Meeting in Washington, DC and were
- Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-extension-study/2459873/UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American Academy of Dermatology Annual Meeting (AAD) in Washington,
- Meet AAD's New Officers and Board of Directorshttps://practicaldermatology.com/news/meet-aads-new-officers-and-board-of-directors/2459880/The American Academy of Dermatology (AAD) is set to install four new officers and four new members of its board of directors at the conclusion of the 2019 AAD Annual Meeting in Washington. The new members will also hold the same positions for the American Academy of Dermatology Associat
- Dr. George J. Hruza Named New AAD Presidenthttps://practicaldermatology.com/news/dr-george-j-hruza-named-new-aad-president/2459881/St. Louis dermatologist George J. Hruza, MD, MBA, FAAD, is set to begin his one-year term as president of the American Academy of Dermatology (AAD) at the conclusion of the 2019 AAD Annual Meeting in Washington. “The health care landscape is evolving, and it’s important for de
- Arkansas Gets SUNucatedhttps://practicaldermatology.com/news/arkansas-gets-sunucated/2459875/Arkansas has joined 18 other states in adopting legislation to allow children to possess and apply sunscreen at school. Governor Asa Hutchinson signed into law HB 1167, which was co-sponsored by Representative Lee Johnson, MD, and carried through the Senate by Senator David Wallace.
- Hyperhidrosis May Up Risk for Anxiety, Depression and ADDhttps://practicaldermatology.com/news/hyperhidrosis-may-up-risk-for-anxiety-depression-and-add/2459877/Individuals with hyperhidrosis are more to have anxiety, depression and attention deficit disorder, according to new research presented at the American Academy of Dermatology’s (AAD) 2019 Annual Meeting in Washington. Of the 500 hyperhidrosis patients involved in the study, 13.8 p
- Study: Isotretinoin Does Not Raise Depression Riskhttps://practicaldermatology.com/news/study-isotretinoin-does-not-raise-depression-risk/2459878/Isotretinoin is not an independent risk factor for depression in adult acne patients, finds new research presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington. “There has been mixed evidence and much debate around the impact of isotretinoin on mo